Roche Holding AG

SWX:ROG Stock Report

Market Cap: CHF 195.4b

Roche Holding Management

Management criteria checks 2/4

Roche Holding's CEO is Thomas Schinecker, appointed in Mar 2023, has a tenure of 2.08 years. directly owns 0% of the company’s shares, worth CHF879.26K. The average tenure of the management team and the board of directors is 5.3 years and 6.6 years respectively.

Key information

Thomas Schinecker

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.1yrs
CEO ownership0.0004%
Management average tenure5.3yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

Roche Holding (VTX:ROG) Will Pay A Larger Dividend Than Last Year At CHF9.70

Mar 17
Roche Holding (VTX:ROG) Will Pay A Larger Dividend Than Last Year At CHF9.70

Roche Holding (VTX:ROG) Has A Pretty Healthy Balance Sheet

Mar 16
Roche Holding (VTX:ROG) Has A Pretty Healthy Balance Sheet

Roche Holding (VTX:ROG) Is Increasing Its Dividend To CHF9.70

Feb 23
Roche Holding (VTX:ROG) Is Increasing Its Dividend To CHF9.70

Roche Holding (VTX:ROG) Is Paying Out A Larger Dividend Than Last Year

Feb 09
Roche Holding (VTX:ROG) Is Paying Out A Larger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Feb 05
Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear
author-image

Roche Holding will see a 4.2576% revenue growth shaking the market

Feb 04### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
author-image

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Feb 02 Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.

Roche Holding AG (VTX:ROG) Could Be Riskier Than It Looks

Nov 25
Roche Holding AG (VTX:ROG) Could Be Riskier Than It Looks

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10
These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17
We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

CEO Compensation Analysis

How has Thomas Schinecker's remuneration changed compared to Roche Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

CHF 8b

Sep 30 2024n/an/a

CHF 9b

Jun 30 2024n/an/a

CHF 11b

Mar 31 2024n/an/a

CHF 11b

Dec 31 2023n/an/a

CHF 11b

Sep 30 2023n/an/a

CHF 11b

Jun 30 2023n/an/a

CHF 11b

Mar 31 2023n/an/a

CHF 12b

Dec 31 2022CHF 5mCHF 1m

CHF 12b

Sep 30 2022n/an/a

CHF 14b

Jun 30 2022n/an/a

CHF 15b

Mar 31 2022n/an/a

CHF 14b

Dec 31 2021CHF 4mCHF 1m

CHF 14b

Sep 30 2021n/an/a

CHF 14b

Jun 30 2021n/an/a

CHF 14b

Mar 31 2021n/an/a

CHF 14b

Dec 31 2020CHF 4mCHF 879k

CHF 14b

Sep 30 2020n/an/a

CHF 14b

Jun 30 2020n/an/a

CHF 13b

Mar 31 2020n/an/a

CHF 13b

Dec 31 2019CHF 2mCHF 609k

CHF 13b

Compensation vs Market: Insufficient data to establish whether Thomas's total compensation is reasonable compared to companies of similar size in the Swiss market.

Compensation vs Earnings: Thomas's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Thomas Schinecker (49 yo)

2.1yrs

Tenure

CHF 5,335,592

Compensation

Dr. Thomas Schinecker is Director since March 27, 2025 at Chugai Pharmaceutical Co., Ltd. He serves as Chairman of the Board at Genentech, Inc. since March 2023. He is Group Chief Executive Officer of Roch...

Leadership Team

NamePositionTenureCompensationOwnership
Severin Schwan
Executive Chairman12.1yrsCHF 11.48m0.043%
CHF 84.2m
Thomas Schinecker
Group Chief Executive Officer2.1yrsCHF 5.34m0.00045%
CHF 879.3k
Alan Hippe
Chief Financial Officer14yrsCHF 6.05m0.0063%
CHF 12.3m
Bruno Eschli
Head of Investor Relationsno datano datano data
Claudia Bockstiegel
General Counsel5yrsno datano data
Pascale Schmidt
Chief Compliance Officer5.3yrsno datano data
Barbara Schadler
Head of Group Communications5.5yrsno datano data
Cristina Wilbur
Chief People Officer9.1yrsCHF 4.25m0.0020%
CHF 3.9m
Nicolas Dunant
Head of Group Media Relationsno datano datano data
Boris L. Zaitra
Head of Corporate Business Developmentno datano datano data
Johannes Clevers
Head of Roche Pharma Research & Early Development3.1yrsCHF 82.50kno data
Cristin Hubbard
Senior Vice President of Immunologyno datano datano data

5.3yrs

Average Tenure

57yo

Average Age

Experienced Management: ROG's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Severin Schwan
Executive Chairman12.1yrsCHF 11.48m0.043%
CHF 84.2m
Ulf Schneider
Director2.1yrsno data0.00063%
CHF 1.2m
Andre Hoffmann
Independent Vice Chairman29.3yrsCHF 400.00k3.54%
CHF 6.9b
Patrick Frost
Independent Non Executive Director5.1yrsCHF 360.00k0.00025%
CHF 488.5k
Richard Lifton
Non-Executive Independent Director10.3yrsCHF 346.71k0%
CHF 0
Anita Hauser
Non-Executive Independent Director8.1yrsCHF 336.16k0.00040%
CHF 781.6k
Jorg Duschmale
Non-Executive Independent Director5.1yrsCHF 394.60kno data
Akiko Iwasaki
Director2.1yrsno datano data
Claudia Ricarda Suessmuth Dyckerhoff
Non-Executive Independent Director9.1yrsCHF 367.02k0.00034%
CHF 664.3k
Jemilah Mahmood
Independent Non-Executive Director3.1yrsCHF 272.50kno data

6.6yrs

Average Tenure

57yo

Average Age

Experienced Board: ROG's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/14 04:17
End of Day Share Price 2025/04/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 58 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research